Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study

Baili, Paolo; Salvo, Francesca Di; Siesling, Sabine; Micheli, Andrea; Lillini, Roberto; Hackl, Monika; Zielonke, N.; Oberaigner, Willi; Eycken, E. Van; Henau, Kris; Valerianova, Z.; Dimitrova, Nadya; Šekerija, Mario; Zvolský, Miroslav; Dušek, Ladislav; Storm, Hans; Engholm, Gerda; Mägi, Margit; Aareleid, Tiiu; Malila, Nea; Seppä, Karri; Velten, Michel; Troussard, Xavier; Bouvier, Véronique; Launoy, Guy; Guizard, A.V.; Faivre, Jean; Bouvier, Anne; Arveux, Patrick; Maynadié, Marc; Woronoff, Anne‐Sophie; Robaszkiewicz, Michel; Baldi, Isabelle; Monnereau, Alain; Trétarre, Brigitte; Bossard, Nadine; Belot, Aurélien; Colonna, Marc; Molinié, F.; Bara, Simona; Schvartz, Claire; Lapôtre-Ledoux, Bénédicte; Grosclaude, Pascale; Meyer, Martin; Stabenow, Roland; Luttmann, Sabine; Eberle, Andrea; Brenner, Hermann; Nennecke, Alice; Engel, Jutta; Schubert-Fritschle, Gabriele; Kieschke, Joachim; Heidrich, Jan; Holleczek, Bernd; Katalinic, Alexander; Jonasson, Jón G.; Tryggvadóttír, Laufey; Comber, Harry; Mazzoleni, Guido; Bulatko, A.; Buzzoni, Carlotta; Giacomin, Adriano; Sardo, Antonella Sutera; Mazzei, A.; Ferretti, Stefano; Crocetti, Emanuele; Manneschi, Gianfranco; Gatta, Gemma; Sant, Milena; Amash, H.; Amati, C.; Baili, Paolo; Berrino, Franco; Bonfarnuzzo, S.; Botta, Laura; Salvo, Francesca Di; Foschi, Roberto; Margutti, C.; Meneghini, Elisabetta; Minicozzi, Pamela; Trama, Annalisa; Serraino, Diego; Zucchetto, Antonella; Angelis, Roberta De; Caldora, M.; Capocaccia, Riccardo; Carrani, E.; Francisci, Silvia; Mallone, Sandra; Pierannunzio, Daniela; Roazzi, Paolo; Rossi, Silvia; Santaquilani, Mariano; Tavilla, Andrea; Pannozzo, Fabio; Natali, M.; Bonelli, Luigina; Vercelli, Marina; Gennaro, Valerio; Ricci, Paolo; Autelitano, M.; Randi, Giorgia; Leòn, Maurizio Ponz de; Marchesi, C.; Crimi, Claudia; Fusco, Mario; Vitale, M.F.; Usala, M.; Traina, Adele; Zarcone, Maurizio; Vitale, Flora; Cusimano, Rosanna; Michiara, Maria; Tumino, Rosario; Rossi, Paolo; Vicentini, Massimo; Falcini, Fabio; Iannelli, A.; Sechi, O.; Cesaraccio, Rosaria; Piffer, Silvano; Madeddu, A; Tisano, F.; Maspero, S.; Fanetti, A.C.; Zanetti, Roberto; Rosso, Stefano; Candela, P.; Scuderi, T.; Stracci, Fabrizio; Rocca, Andrea; Tagliabue, Giovanna; Contiero, Paolo; Tos, Angelo Paolo Dei; Tognazzo, S; Pildava, Santa; Smailytė, Giedrė; Calleja, Neville; Micallef, R.; Johannesen, T.B.; Rachtan, Jadwiga; Góźdż, Stanisław; Mężyk, Ryszard; Błaszczyk, Jerzy; Kępska, Kamila; Bielska–Lasota, Magdalena; Lacerda, G. Forjaz de; Bento, Maria José; Antunes, Luís; Miranda, A.; Mayer-da-Silva, A.; Nicula, Florian; Coza, Daniela; Diba, C. Safaei; Primic-Žakelj, Maja; Almar, Enrique; Mateos, Antonio Navareño; Errezola, M.; Larrañaga, Nerea; Torrella-Ramos, A.; García, J.M. Díaz; Marcos-Navarro, A.I.; Marcos‐Gragera, Rafael; Vilardell, L.; Yuste-Sánchez, María José; Molina, Esther; Navarro, Carmen; Chirlaque, María‐Dolores; Moreno‐Iribas, Conchi; Ardanáz, Eva; Galcerán, Jaume; Carulla, Marià; Lambe, Mats; Khan, S.; Mousavi, M.; Bouchardy, Christine; Usel, M.; Frick, Harald; Lorez, Matthias; Ess, Silvia; Herrmann, Christian; Bordoni, Andrea; Spitale, Alessandra; Konzelmann, Isabelle; Visser, Otto; Lemmens, V.; Coleman, Michael P.; Allemani, Claudia; Rachet, Bernard; Verne, Julia; Easey, N.; Lawrence, Gill; Morán, Teresa; Rashbass, Jem; Roche, M.; Wilkinson, J.; Gavin, Anna; Fitzpatrick, Deirdre; Brewster, David H.; Huws, Dyfed Wyn; White, C.; Otter, Renée

doi:10.1016/j.ejca.2015.07.025

Cited by 71 publications

(39 citation statements)

References 44 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the third novelty, we showed that mortality of SPCs was in line with known mortality of first primary cancers. Both the most fatal (esophageal, liver, lung and stomach) and least fatal (endocrine, skin) cancers were among those predicted from survival studies among first cancers . Unexpectedly, for CUP as SPC other neoplasia was given as the cause of death in over half of the patients.…”

Section: Discussionmentioning

confidence: 91%

Second primary cancers in non‐Hodgkin lymphoma: Family history and survival

Chattopadhyay

Zheng

Sud

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

Second primary cancers (SPCs) account for an increasing proportion of all cancer diagnoses and family history of cancer may be a risk factor for SPCs. Using the Swedish Family‐Cancer Database on non‐Hodgkin lymphoma (NHL), we assessed the influence of family history on risk of SPCs and of SPCs on survival. NHL patients were identified from the years 1958 to 2015 and generalized Poisson models were used to calculate relative risks (RRs) for SPCs and familial SPCs. Among 14,393 NHL patients, a total of 1,866 (13.0%) were diagnosed with SPC. Familial risk of nine particular cancers was associated with risks of these cancers as SPCs, with twofold to fivefold increase in RRs. At the end of a 25‐year follow‐up period, the survival probability for persons with SPC was only 20% of that for patients without SPC; the hazard ratio for SPC was 1.59 (95% CI: 1.46–1.72). Survival could be predicted by the prognostic groups based on first cancers and HRs increase systematically with worse prognosis yielding a trend of p = 4.6 × 10−5. SPCs had deleterious consequences for survival in NHL patients. Family history was associated with increasing numbers of SPCs. Prevention of SPCs and their early detection is an important target in the overall strategy to improve survival in NHL patients. Counseling for avoidance of risk factors and targeted screening based on family history are feasible steps in risk reduction.

show abstract

Section: Discussionmentioning

confidence: 91%

Second primary cancers in non‐Hodgkin lymphoma: Family history and survival

Chattopadhyay

Zheng

Sud

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Further, the recently published EUROCARE-5 study also identified regional differences in lung cancer survival [19]. Cancer survival was associated with economic factors such as investment into a country's healthcare system [20]. The additional survival benefit of the German and Western European subpopulations from necitumumab might thus be associated with differences in healthcare systems and routine patient care, which might have caused imbalances, e.g., regarding the access to optimal treatment for comorbidities or the optimal post-study treatments [21,22].…”

Section: Discussionmentioning

confidence: 98%

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

et al. 2016

View full text Add to dashboard Cite

secondary endpoints included progression-free survival (PFS), safety and health-related quality of life (EQ-5D, Lung Cancer Symptom Scale (LCSS)). Results: The 96 German SQUIRE patients with EGFR-expressing tumors (GC + N 42, GC 54) received a median of 4 GC cycles; the GC + N patients received 5 cycles of necitumumab. Adding necitumumab was associated with 41% risk reduction of death (hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.37-0.94, p = 0.026) and 44% risk reduction of progression (HR 0.56, 95% CI 0.33-0.95, p = 0.029). Adverse events typically associated with EGFR antibody treatment (including rash, hypomagnesemia) were more common with GC + N. The time to deterioration of the EQ-5D and LCSS scores showed no notable differences between the treatment arms, except for appetite loss (delayed for GC + N). Conclusion: The survival benefit from adding necitumumab to first-line GC was more pronounced in the German SQUIRE subpopulation with EGFR-expressing tumors than in the overall (intentionto-treat) population; toxicity was manageable and consistent with the overall population.

show abstract

“…Wiedza ta ma fundamentalne znaczenie dla określania potrzeb i budowania strategii walki z rakiem oraz w ocenie jej efektywności zdrowotnej. [19,20,[22][23][24][25].…”

Section: Dyskusjaunclassified

“…W kolejnych edycjach EUROCARE korelację pomiędzy wyleczalnością nowotworów i wartością produktu krajowego brutto (GDP -Gross Demostic Product) oraz wydatkami na zdrowie (TNEHTotal National Expediture health) wykazali Micheli i wsp., a ostatnio Baili i wsp. [22,23]. Wysokie wartości TNEH w Europie Zachodniej i Centralnej korespondowały z wysokimi wskaźnikami przeżyć.…”

Section: Dyskusjaunclassified

Zróżnicowanie wyleczalności chorych na wybrane nowotwory złośliwe w Polsce na tle krajów europejskich w latach 2005–2009 na podstawie badania CONCORD 2

Bielska–Lasota¹,

Krzyżak²,

Kwiatkowska³

et al. 2016

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Wstęp. Wskaźniki 5-letnich przeżyć populacyjnych obrazują poziom wyleczalności nowotworów złośliwych w populacji, a zatem są jednym z najważniejszych narzędzi do oceny efektywności walki z rakiem. Dzięki ujednoliconej metodologii ogólnoświatowego badania CONCORD 2 wskaźniki obliczone dla Polski można było porównać z innymi krajami Europy. Celem opracowania była ocena wyleczalności chorych na wybrane nowotwory w Polsce oraz w niektórych województwach na tle krajów europejskich. Wyniki. W Polsce u chorych na raka gruczołu krokowego (74%), piersi (74%), szyjki macicy (53%), okrężnicy (50%), odbytnicy (47%), jajnika (34%) i żołądka (19%) wskaźniki 5-letnich przeżyć należały do najniższych w Europie. Natomiast u chorych na białaczki (49%) i raka płuca (13%) przeżycia były na poziomie przeciętnych w Europie. Analiza według województw wykazała zróżnicowanie regionalne. Największe różnice dotyczyły białaczek w województwach dolnośląskim i świętokrzyskim (14%), raka gruczołu krokowego w wielkopolskim i świętokrzyskim (10%) oraz raka piersi w wielkopolskim i podkarpackim (6%), co wskazuje na zróżnicowanie w standardach profilaktyki i leczenia. Wnioski. Badanie wykazało zróżnicowanie wskaźnika 5-letnich przeżyć w Europie na niekorzyść Polski. W nowotworach dobrze rokujących takich jak: rak gruczołu krokowego, piersi, okrężnicy i odbytnicy wskaźniki należały do najniższych w Europie, natomiast u chorych na raka płuca oraz białaczki były na poziomie przeciętnych w Europie. Differences in treatment outcomes

show abstract

Age and case mix-standardised survival for all cancer patients in Europe 1999–2007: Results of EUROCARE-5, a population-based study

Cited by 71 publications

References 44 publications

Second primary cancers in non‐Hodgkin lymphoma: Family history and survival

Second primary cancers in non‐Hodgkin lymphoma: Family history and survival

Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE)

Zróżnicowanie wyleczalności chorych na wybrane nowotwory złośliwe w Polsce na tle krajów europejskich w latach 2005–2009 na podstawie badania CONCORD 2

Contact Info

Product

Resources

About